Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial(Nature Medicine, 10.1038/s41591-024-03025-3)

Roger Li; Paras H. Shah; Tyler F. Stewart; Jong Kil Nam; Trinity J. Bivalacqua; Donald L. Lamm; Edward M. Uchio; Daniel M. Geynisman; Joseph M. Jacob; Joshua J. Meeks; Rian Dickstein; Shane M. Pearce; Seok Ho Kang; Seung Il Jung; Ashish M. Kamat; James M. Burke; Kirk A. Keegan; Gary D. Steinberg

doi:10.1038/s41591-024-03137-w

Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial(Nature Medicine, 10.1038/s41591-024-03025-3)

Roger Li^*, Paras H. Shah, Tyler F. Stewart, Jong Kil Nam, Trinity J. Bivalacqua, Donald L. Lamm, Edward M. Uchio, Daniel M. Geynisman, Joseph M. Jacob, Joshua J. Meeks, Rian Dickstein, Shane M. Pearce, Seok Ho Kang, Seung Il Jung, Ashish M. Kamat, James M. Burke, Kirk A. Keegan, Gary D. Steinberg

^*Corresponding author for this work

Urology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-024-03025-3, published online 6 June 2024 In the version of the article initially published, the text “Immune-related adverse effects were exclusively associated with pembrolizumab” and, in the following sentence, also referring to adverse effects, “…all related to pembrolizumab” has been removed from the Abstract. In the final paragraph of the Results, “assessed by the treating physicians” has been inserted after “Related adverse effect to pembrolizumab…”. These changes have been made to the HTML and PDF versions of the article.

Original language	English (US)
Pages (from-to)	2372
Number of pages	1
Journal	Nature Medicine
Volume	30
Issue number	8
DOIs	https://doi.org/10.1038/s41591-024-03137-w
State	Published - Aug 2024

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41591-024-03137-w

Cite this

Li, R., Shah, P. H., Stewart, T. F., Nam, J. K., Bivalacqua, T. J., Lamm, D. L., Uchio, E. M., Geynisman, D. M., Jacob, J. M., Meeks, J. J., Dickstein, R., Pearce, S. M., Kang, S. H., Jung, S. I., Kamat, A. M., Burke, J. M., Keegan, K. A., & Steinberg, G. D. (2024). Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial(Nature Medicine, 10.1038/s41591-024-03025-3). Nature Medicine, 30(8), 2372. https://doi.org/10.1038/s41591-024-03137-w

@article{a1c57b0138614301ac81e53b179adcb2,

title = "Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial(Nature Medicine, 10.1038/s41591-024-03025-3)",

abstract = "Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-024-03025-3, published online 6 June 2024 In the version of the article initially published, the text “Immune-related adverse effects were exclusively associated with pembrolizumab” and, in the following sentence, also referring to adverse effects, “…all related to pembrolizumab” has been removed from the Abstract. In the final paragraph of the Results, “assessed by the treating physicians” has been inserted after “Related adverse effect to pembrolizumab…”. These changes have been made to the HTML and PDF versions of the article.",

author = "Roger Li and Shah, {Paras H.} and Stewart, {Tyler F.} and Nam, {Jong Kil} and Bivalacqua, {Trinity J.} and Lamm, {Donald L.} and Uchio, {Edward M.} and Geynisman, {Daniel M.} and Jacob, {Joseph M.} and Meeks, {Joshua J.} and Rian Dickstein and Pearce, {Shane M.} and Kang, {Seok Ho} and Jung, {Seung Il} and Kamat, {Ashish M.} and Burke, {James M.} and Keegan, {Kirk A.} and Steinberg, {Gary D.}",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Nature America, Inc. 2024.",

year = "2024",

month = aug,

doi = "10.1038/s41591-024-03137-w",

language = "English (US)",

volume = "30",

pages = "2372",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "8",

}

Li, R, Shah, PH, Stewart, TF, Nam, JK, Bivalacqua, TJ, Lamm, DL, Uchio, EM, Geynisman, DM, Jacob, JM, Meeks, JJ, Dickstein, R, Pearce, SM, Kang, SH, Jung, SI, Kamat, AM, Burke, JM, Keegan, KA & Steinberg, GD 2024, 'Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial(Nature Medicine, 10.1038/s41591-024-03025-3)', Nature Medicine, vol. 30, no. 8, pp. 2372. https://doi.org/10.1038/s41591-024-03137-w

Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial(Nature Medicine, 10.1038/s41591-024-03025-3). / Li, Roger; Shah, Paras H.; Stewart, Tyler F. et al.
In: Nature Medicine, Vol. 30, No. 8, 08.2024, p. 2372.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Author Correction

T2 - Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial(Nature Medicine, 10.1038/s41591-024-03025-3)

AU - Li, Roger

AU - Shah, Paras H.

AU - Stewart, Tyler F.

AU - Nam, Jong Kil

AU - Bivalacqua, Trinity J.

AU - Lamm, Donald L.

AU - Uchio, Edward M.

AU - Geynisman, Daniel M.

AU - Jacob, Joseph M.

AU - Meeks, Joshua J.

AU - Dickstein, Rian

AU - Pearce, Shane M.

AU - Kang, Seok Ho

AU - Jung, Seung Il

AU - Kamat, Ashish M.

AU - Burke, James M.

AU - Keegan, Kirk A.

AU - Steinberg, Gary D.

PY - 2024/8

Y1 - 2024/8

N2 - Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-024-03025-3, published online 6 June 2024 In the version of the article initially published, the text “Immune-related adverse effects were exclusively associated with pembrolizumab” and, in the following sentence, also referring to adverse effects, “…all related to pembrolizumab” has been removed from the Abstract. In the final paragraph of the Results, “assessed by the treating physicians” has been inserted after “Related adverse effect to pembrolizumab…”. These changes have been made to the HTML and PDF versions of the article.

AB - Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-024-03025-3, published online 6 June 2024 In the version of the article initially published, the text “Immune-related adverse effects were exclusively associated with pembrolizumab” and, in the following sentence, also referring to adverse effects, “…all related to pembrolizumab” has been removed from the Abstract. In the final paragraph of the Results, “assessed by the treating physicians” has been inserted after “Related adverse effect to pembrolizumab…”. These changes have been made to the HTML and PDF versions of the article.

UR - http://www.scopus.com/inward/record.url?scp=85196176503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85196176503&partnerID=8YFLogxK

U2 - 10.1038/s41591-024-03137-w

DO - 10.1038/s41591-024-03137-w

M3 - Comment/debate

C2 - 38890533

AN - SCOPUS:85196176503

SN - 1078-8956

VL - 30

SP - 2372

JO - Nature Medicine

JF - Nature Medicine

IS - 8

ER -

Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial(Nature Medicine, 10.1038/s41591-024-03025-3)

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this